KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $23.5 million.

  • Adaptive Biotechnologies' Cost of Revenue rose 1420.37% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.7 million, marking a year-over-year increase of 772.71%. This contributed to the annual value of $84.8 million for FY2024, which is 431.25% down from last year.
  • Per Adaptive Biotechnologies' latest filing, its Cost of Revenue stood at $23.5 million for Q3 2025, which was up 1420.37% from $23.6 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Cost of Revenue high stood at $26.7 million for Q4 2021, and its period low was $20.3 million during Q2 2024.
  • Its 5-year average for Cost of Revenue is $22.9 million, with a median of $23.0 million in 2025.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 7237.11% in 2021, then tumbled by 1490.45% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Cost of Revenue (Quarter) stood at $26.7 million in 2021, then dropped by 11.16% to $23.7 million in 2022, then dropped by 7.63% to $21.9 million in 2023, then dropped by 1.51% to $21.6 million in 2024, then grew by 8.78% to $23.5 million in 2025.
  • Its Cost of Revenue stands at $23.5 million for Q3 2025, versus $23.6 million for Q2 2025 and $23.0 million for Q1 2025.